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INTRODUCTION
Despite its declining incidence in many countries, gastric
cancer remains one of the most prevalent malignancies in
many countries, and a major international health problem.
According to statistics published in 2002, gastric cancer
remained the most prevalent cancer in Korea (1). Recently,
improvements in early diagnosis have increased the number
of patients suitable for curative resection, but tumor recur-
rence is frequently observed. Moreover, many patients have
metastatic disease at the time of initial diagnosis.
Cytotoxic chemotherapy has been demonstrated to be effec-
tive in the palliative management of unresectable locally ad-
vanced or metastatic gastric cancer. Randomized trials have
found that cytotoxic chemotherapy is associated with imp-
rovement in overall survival (OS) and quality of life as com-
pared with best supportive care (2-4). Until recently, 5-fluo-
rouracil (5-FU) and platinum-based combination chemother-
apy has been commonly used as first-line treatment in unre-
sectable locally advanced or metastatic gastric cancer (5, 6).
In a phase III randomized study, Kim et al. reported an over-
all response rate of 51% and a median OS of 9.0 months in
previously untreated gastric cancer patients with 5-FU/cis-
platin (FP) chemotherapy (5). However, the overall progno-
sis of patients failing first-line chemotherapy is poor, and
although many of these patients are candidates for second-line
chemotherapy at the time of first-line treatment failure, no
established second-line chemotherapeutic regimen is available
as yet.
Paclitaxel is an anticancer agent that promotes the forma-
tion of tubulin dimers and that inhibits microtubule depoly-
merization. Paclitaxel has broad spectrum antitumor activi-
ty and moderate toxicity profiles. It has shown encouraging
activity as a single agent (200-225 mg/m2, every 3 weeks)
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Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line
Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer
This study was performed to evaluate the efficacy and toxicity of low-dose paclita-
xel/cisplatin chemotherapy in patients with metastatic or recurrent gastric cancer
that had failed 5-fluorouracil/platinum-based chemotherapy. Thirty-two patients with
documented progression on or within 6 months after discontinuing 5-fluorouracil/plat-
inum-based chemotherapy were enrolled. As a second-line treatment, paclitaxel
(145 mg/m
2) and cisplatin (60 mg/m
2) was administered on day 1 every 3 weeks.
Among 32 patients enrolled, 8 (25%) responded partially to paclitaxel/cisplatin, 8
(25%) had stable disease, and 14 (44%) had progressive disease. Two patients
(6%) were not evaluable. The median time to progression (TTP) and overall sur-
vival for all patients were 2.9 months and 9.1 months, respectively. The most com-
mon hematologic toxicity was anemia (47%). Grade 3 neutropenia developed in
three patients (9%), but no other grade 3/4 hematologic toxicity occurred. The most
common non-hematologic toxicities were emesis (31%) and peripheral neuropa-
thy (38%). Three cases (9%) of grade 3/4 emesis and 2 cases (6%) of grade 3
peripheral neuropathy developed. In conclusion, low-dose paclitaxel and cisplatin
chemotherapy showed moderate activity with favorable toxicity profiles. However,
relatively short TTP of this regimen warrants the development of more effective
paclitaxel-based regimens other than combination with cisplatin in these patients
as second-line therapies. 
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in gastric cancer, with a response rate of 17-28% (7-10). Pacli-
taxel appears to have a schedule-dependent synergy with plat-
inum compounds, as documented in human gastric cancer
cell lines (11), and this observed synergy has led to the devel-
opment of paclitaxel-platinum combination regimens in a
number of solid tumors, including gastric cancer (12-16).
In gastric cancer, first-line paclitaxel/cisplatin chemothera-
py has shown response rates of 44-46% and median OS of
11.2-13.8 months (13, 15, 16). Although these reports are
of phase II studies, treatment outcomes of paclitaxel and cis-
platin chemotherapy seem to be at least similar to those of
previously commonly used two- or three-drug combination
regimens (FAMTX [5-FU, doxorubicin, and methotrexate]
(17), ELF [etoposide, leucovorin, and 5-FU] (17), and FP [5-
FU and cisplatin] (5, 17)).
We previously conducted a phase II study using low-dose
paclitaxel 145 mg/m2 plus cisplatin 60 mg/m2 on day 1 every
3 weeks in non-small cell lung cancer. In that study, this regi-
men was feasible and seemed to have reduced toxicities and
maintain efficacy compared with previously reported other
regimens (18). This previous experience and convenience of
the scheduling in the outpatient setting prompted us to select
the same regimen in gastric cancer. Based on in vitro syner-
gistic effects (11) and feasibility of low-dose paclitaxel and
cisplatin regimen (18), a phase II study was performed in
gastric cancer patients that had failed previous 5-FU/plat-
inum chemotherapy at three institutions. 
MATERIALS AND METHODS
Eligibility 
To be eligible for this study, patients were required to have:
histologically confirmed adenocarcinoma of the stomach (ex-
cept carcinomas of the esophagogastric junction) that pro-
gressed while receiving, or within 6 months after the discon-
tinuation of prior 5-FU/platinum-based chemotherapy used
as an adjuvant or palliative treatment. In addition, patients
were required to be 18-75 yr old with a life expectancy of
>3 months and have an Eastern Cooperative Oncology Group
(ECOG) performance status of 0 to 2, adequate hematologic
counts (absolute neutrophil count [ANC] ≥1.5×109/L and
platelet count≥100×109/L), and laboratory results within
the following limits (serum bilirubin ≤1.25×upper nor-
mal limit [UNL], serum aspartate aminotransferase [AST]
and alanine aminotransferase [ALT] ≤2.5×UNL, serum
alkaline phosphatase ≤5.0×UNL [unless bone metastasis
was present in the absence of any liver disease]) and renal
function (serum creatinine ≤1.5 mg/dL). All patients were
required to have at least one measurable disease (defined as a
mass with demarcated dimensions by computed tomogra-
phy [CT], routine chest radiography, or by physical exami-
nation). 
Patients were deemed ineligible if they had brain metas-
tasis or a history of a prior or a concomitant malignancy, except
for curatively treated non-melanoma skin cancer or in situ
cervical cancer. Pre-existing motor or sensory neurologic sym-
ptoms of ≥grade 2 according to the National Cancer Insti-
tute Common Toxicity Criteria (NCI-CTC) were not per-
mitted, nor were active infections or other serious underly-
ing medical conditions that might have impaired the ability of
a patient to receive protocol treatment. All patients provid-
ed written informed consent, and this study was approved by
institutional review boards. 
Treatment 
Hydrocortisone (100 mg), pheniramine maleate, and famo-
tidine were administered intravenously (i.v.) 30 min before
paclitaxel for hypersensitivity prophylaxis. The patients then
received paclitaxel 145 mg/m2 as a 3-hr i.v. infusion, followed
by cisplatin 60 mg/m2 as a 15-min i.v. infusion with a stan-
dard hydration method on day 1. All patients received ade-
quate antiemetic therapy prior to chemotherapy. Treatment
was administered on an outpatient basis and repeated 3 weekly,
provided that patients had recovered from toxic effects. This
combination chemotherapy was continued for up to 6 cycles
in the absence of disease progression or unacceptable toxici-
ty. Granulocyte colony-stimulating factor (G-CSF) was not
routinely administered.
Response to treatment and adverse effects
Physical examination, complete blood counts and bioche-
mical tests were carried out before each cycle of therapy. Tu-
mors were measured every 2 cycles by imaging studies. Res-
ponse was assessed using WHO criteria. Complete response
(CR) was defined as the disappearance of all clinical evidence
of tumor for a period of at least 4 weeks. Partial response (PR)
was defined as a sustained ≥50% decrease in bidimensional
tumor measurements for a period of at least 4 weeks, with-
out the appearance of any new lesions or the progression of
any existing lesion. Progressive disease (PD) was defined as
the development of any new lesion or a greater than 25%
increase in the sum of the products of all measurable lesions.
Stable disease (SD) was defined as a tumor response that did
not meet the above CR, PR or PD criteria. 
Toxicities were evaluated using NCI-CTC (version 2.0)
before each treatment. Dose modifications and treatment
delays were performed as necessary according to the extent
of hematological and non-hematological toxicities. Drug
doses were reduced by 25% in case of grade 4 neutropenia
(ANC <0.5×109/L), grade 4 thrombocytopenia (platelet
count <25×109/L) or febrile neutropenic fever. Additional
25% reduction of both drug doses was indicated for recur-
rent febrile neutropenic fever, grade 4 neutropenia or throm-
bocytopenia. For patients who experienced grade 1 nephro-Second-line Paclitaxel/Cisplatin for Gastric Cancer S117
toxicity, grade 2/3 peripheral neuropathy or other severe non-
hematologic toxicities of NCI-CTC ≥grade 3, drug doses
were reduced by 25%. If a patient had ≥grade 2 non-hema-
tological toxicities during chemotherapy (except alopecia),
chemotherapy was withheld for a minimum of 1 week until
the patient had improved to ≤grade 1, at which time che-
motherapy was re-instituted. However, if hematologic or
non-hematological toxicities did not improve to ≤grade 1
after 3 weeks, the patient was removed from the study. Both
chemotherapeutic drugs were discontinued in the event of
transitory ≥grade 2 nephrotoxicity, grade 4 neuropathy, and
if severe toxicity recurred despite dose reduction.
Statistical analysis 
The primary endpoint of this trial was the response rate to
low-dose paclitaxel/cisplatin treatment. TTP and OS were
secondary end points. TTP was calculated from the first day
of chemotherapy to the date of disease progression, and OS
was calculated from the first day of chemotherapy until death.
This trial was designed to detect a response rate of 20% as
compared to a minimal, clinically meaningful response rate
of 5%. An optimal Simon two-step design was used (19),
with a power of 80% to accept the hypothesis and a 5% sig-
nificance to reject the hypothesis. Ten patients were initially
recruited, with the intention that had no responses been ob-
served, the trial would have been discontinued. However, it
was planned to continue with the trial and to recruit a total
of 29 patients with measurable disease, if at least one of these
10 patients showed an objective response. Allowing for a fol-
low-up loss rate of 10%, a total sample size of 32 patients was
necessary. Analyses of TTP and OS curves were performed
using the Kaplan-Meier method. 
RESULTS
Patient characteristics
From October 2002 to January 2005, 32 patients of medi-
an age 60.5 yr (29-74 yr) were enrolled from three institu-
tions. Patient characteristics are given in Table 1. The major-
ity of the study population was male (84%, 27 of 32). Eleven
patients (34%) had an ECOG performance status of 2. Twen-
ty-four patients (75%) had previously received 5-FU/cisplatin
(FP) chemotherapy and 8 patients (25%) 5-FU/leucovorin/
oxaliplatin (FOLFOX) chemotherapy. Of these patients, 6
(19%) received FP chemotherapy in an adjuvant setting. At
the time of enrollment, 23 patients (72%) had progressive
disease during prior 5-FU/platinum-based chemotherapy
and 9 (28%) progressed within 6 months of discontinuing
previous chemotherapy. All patients had measurable tumor
lesions. Lymph nodes (69%), liver (44%) and peritoneum
(41%) were the most common metastatic sites. 
Drug delivery 
Of the 32 patients who received second-line chemothera-
py, 2 patients (6%) were non-evaluable for response due to
early drop-out after the first cycle; one patient withdrew con-
sent and received further treatment at other hospital, and the
other patient refused further chemotherapy due to treatment-
related toxicity (severe emesis). 
A total of 108 treatment cycles were delivered, with a medi-
an of 3 cycles per patient (range, 1 to 6). Seven (22%) of the
patients received the planned 6 cycles of chemotherapy. Treat-
ment was discontinued prematurely in two patients because
of chemotherapy-associated toxicities; one patient, as men-
tioned above, rejected further treatment due to severe eme-
sis after the first cycle of chemotherapy, and the other patient
could not receive further chemotherapy because of severe peri-
pheral neuropathy. Relative dose intensities were calculated
for all patients and drugs according to the method described
by Hryniuk (20). The calculated mean relative dose intensities
of paclitaxel and cisplatin were 93% and 93%, respectively. 
Objective tumor responses
Of the 32 patients who received second-line combination
chemotherapy, 2 patients (6%) were not evaluable for res-
Patient characteristics (N=32)
No. of patients enrolled 32 (100%)
Assessable for response 30 (94%)
Assessable for toxicity 32 (100%)
Median age (range) 60.5 yr (29-74)
Gender (Male:Female) 27 (84%):5 (16%)
ECOG performance status (0-1:2) 21 (66%):11 (34%)
Organ involvement
Lymph nodes 22 (69%)
Liver 14 (44%)
Peritoneum 13 (41%)
Abdomino-pelvic mass 5 (16%)
Lung/Pleura 4 (13%)
Adrenal gland 1 (3%)
Bone 1 (3%)
No. of organs involved
1 8 (25%)
2 11 (34%)
≥3 13 (41%)
Median no. of organs involved (range) 2 (1-6)
Prior chemotherapy
5-FU/Cisplatin (FP) 24 (75%)
No. of cycles: Median (range) 6 (1-12)
5-FU/Leucovorin/Oxaliplatin (FOLFOX) 8 (25%)
No. of cycles: Median (range) 3 (1-6)
Disease status at enrollment
Progression during previous chemotherapy 23 (72%)
Progression after discontinuing previous  9 (28%)
chemotherapy
Table 1. Patient characteristicsS118 K.-W. Lee, J.H. Kim, T. Yun, et al.
ponse. By intent-to-treat analysis, the overall response rate
was 25% (95% confidence interval [CI]: 13-42%) and 8 of
the 32 patients achieved PR. Eight patients (25%) had SD,
and 14 patients (44%) tumor progression. Seven of 24 pa-
tients in the FP group (29%) and 1 of 8 in the FOLFOX
group (13%) responded to second-line chemotherapy. 
Adverse events
Toxicities were evaluated in all 32 patients, and results are
summarized in Table 2. The most common hematologic tox-
icity was anemia (47%). Of the grade 3 or 4 hematologic tox-
icities, 3 cases (9%) of grade 3 neutropenia occurred. No grade
3 or 4 anemia or thrombocytopenia was observed, and no pa-
tient experienced febrile neutropenia. 
Non-hematologic toxicities consisted mainly of emesis and
Fig. 1. Time to progression and overall survival curves.
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Adverse events
Hematologic toxicities
Neutropenia 9 (28%) 3 (9%) 0 (0%)
Anemia 15 (47%) 0 (0%) 0 (0%)
Thrombocytopenia 1 (3%) 0 (0%) 0 (0%)
Neutropenic fever 0 (0%) - -
Non-hematologic toxicities
Emesis 10 (31%) 2 (6%) 1 (3%)
Diarrhea 4 (13%) 0 (0%) 0 (0%)
Hepatotoxicity 8 (25%) 0 (0%) 0 (0%)
Nephrotoxicity 3 (9%) 0 (0%) 0 (0%)
Peripheral neuropathy 12 (38%) 2 (6%) 0 (0%)
Table 2. Adverse events
Study Treatment Dose and schedule
Neutro-
penia
(Grade 
3 or 4)
Response
rate
No. of
patients
Peripheral 
neuro-
pathy
(Total)
Peripheral
neuropathy
(Grade 
3 or 4)
Kornek et al. (13) First-line chemotherapy P: 160 mg/m
2 (3-hr infusion, Day 1) 45 44% 33% 49% 13%
C: 60 mg/m
2 (1-hr infusion, Day 1)
(every 2 weeks, with or without G-CSF)
Gadgeel et al. (14)  First-line chemotherapy P: 200 mg/m
2 (3-hr infusion, Day 1) 27 33% 33% 50% 8%
Cb: AUC of 5.0 (Day 1)
(every 3 weeks)
Park et al. (15)  First-line chemotherapy P: 175 mg/m
2 (3-hr infusion, Day 1) 36 46% 29% 54% 9%
C: 75 mg/m
2 (Day 1)
(every 3 weeks)
Lee et al. (16)  First-line chemotherapy P: 145 mg/m
2 (3-hr infusion, Day 1) 39 44% 14% 43% 3%
C: 60 mg/m
2 (15-min infusion, Day 1)
(every 3 weeks)
Shin et al. (31) First-line or second-line  P: 175 mg/m
2 (3-hr infusion, Day 1) 37 27% 27% NR 3%
chemotherapy C: 70 mg/m
2 (1-hr infusion, Day 1)
(every 3 weeks)
Stathopoulos  Second-line  P: 175 mg/m
2 (3-hr infusion, Day 1) 47 28% 9% 85% 0%
et al. (21) chemotherapy Cb: AUC of 5.0 (Day 1)
(every 3 weeks)
Chang et al. (30) Second-line chemotherapy P: 200 mg/m
2 (3-hr infusion, Day 1) 45 22% 40% 67% 2%
Cb: AUC of 6.0 (Day 1)
(every 3 weeks)
This study Second-line chemotherapy P: 145 mg/m
2 (3-hr infusion, Day 1) 32 25% 9% 38% 6%
C: 60 mg/m
2 (15-min infusion, Day 1)
(every 3 weeks)
Table 3. Efficacy and toxicities of paclitaxel and platinum doublet chemotherapy in gastric cancer patients
P, paclitaxel; C, cisplatin; Cb, carboplatin; AUC, Area under the concentration-time curve; G-CSF, granulocyte colony-stimulating factor; NR, not reported.peripheral neuropathy. Nausea and vomiting occurred in 10
patients (31%) and was generally mild or moderate. Grade
3 or 4 emesis was noted in 3 patients (9%). Twelve patients
(38%) developed peripheral neuropathy, which was general-
ly mild, but two patients (6%) experienced severe (grade 3)
peripheral neuropathy. Liver function test abnormalities were
observed in 8 patients (25%), but all were mild and transient.
Mild diarrhea and nephrotoxicity were noted in 4 (13%) and
3 patients (9%), respectively. No patient experienced infu-
sion-related hypersensitivity during chemotherapy. Two pati-
ents dropped out of the study because of adverse events after
chemotherapy. One patient rejected further treatment due to
severe emesis, and the other could not receive further chemo-
therapy due to severe peripheral neuropathy. No treatment-
related death occurred.
Survival
The median follow-up duration was 9.3 months. Median
TTP after the initiation of low-dose paclitaxel/cisplatin che-
motherapy was 2.9 months (95% CI: 1.8-4.0 months) (Fig.
1), and the median TTP of responders (N=8) was 4.3 months
(95% CI: 3.1-5.5 months). After paclitaxel/cisplatin chemo-
therapy failure, 23 patients received third-line chemothera-
py. As of reference date of final analysis (20 December 2005),
31 patients (97%) were found to have died of their disease.
The median OS of all patients was 9.1 months (95% CI: 7.7-
10.5 months) (Fig. 1), and the median OS of responders (N=
8) was 11.2 months (95% CI: 6.2-16.2 months). 
DISCUSSION
The median survival of gastric cancer patients administered
palliative chemotherapy has been reported to be longer than
that of patients receiving best supportive care (2-4). In addi-
tion to the significant survival advantage associated with che-
motherapy, the patients that received therapy were observed
to have a more stable quality of life. However, the clinical
benefit of salvage chemotherapy has not been proven, and no
randomized controlled trial data suggest a benefit for second-
line chemotherapy. Some studies have suggested that patients
who respond to second-line chemotherapy survive longer than
non-responders and that symptomatic benefit may be obtained
from second-line therapy (8, 21), but other studies have failed
to demonstrate the effectiveness of second-line treatment.
These different results concerning the benefits of second-line
chemotherapy in gastric cancer may be attributable to vari-
ability in responsiveness to first-line chemotherapy, and to
the chemotherapeutics previously used.
Paclitaxel has a cytotoxic mechanism that is different from
those of older chemotherapeutic agents such as 5-FU and
platinum. It has been reported that paclitaxel alone attained
response rates of 20-22% in patients with gastric carcinoma
refractory to prior chemotherapy (8, 22). In previous reports
on the dose-response effect of paclitaxel, no obvious benefit
was observed for high-dose paclitaxel in various solid tumors,
including head and neck (23), lung (24), breast (25, 26), and
ovary cancer (27, 28). Moreover, it has been consistently re-
ported that higher-dose paclitaxel has no additional survival
benefit in various solid tumors. We previously performed
phase II study using low-dose paclitaxel (145 mg/m2) and
cisplatin (60 mg/m2) on day 1 every 3 weeks as first-line che-
motherapy for gastric cancer. The overall response rate was
44% and median TTP and OS were 4.7 and 12.1 months,
respectively. These results also suggested a similar efficacy
for low- and high-dose paclitaxel-containing regimens in
advanced gastric cancer patients (16). Paclitaxel binding sites
on  -tubulin were found to be saturated at the paclitaxel
plasma steady-state concentrations achieved by doses ≥135
mg/m2 (24-hr infusion), and cytotoxicity was observed to
plateau in vitro on increasing the paclitaxel concentration
(29). These observations may explain the lack of additional
survival benefit in solid tumors treated with higher doses of
paclitaxel.
The present study was performed using a low-dose pacli-
taxel/cisplatin regimen as a second-line treatment for gastric
cancer patients who had failed previous 5-FU/platinum-based
chemotherapies at three institutions. To our knowledge, this
is the first study to report the efficacy of paclitaxel/cisplatin
as second-line chemotherapy in gastric cancer. In the present
study, toxicities were generally mild. The major toxicities
were anemia, peripheral neuropathy, emesis, and neutrope-
nia, which are similar to those previously reported for higher-
dose paclitaxel/platinum-containing regimens. However, grade
3 or 4 neutropenia developed only in 9% of patients, which
is substantially lower than those reported for higher-dose pa-
clitaxel/platinum-containing regimens (Table 3). Peripheral
neuropathy is the most troublesome toxicity for patients receiv-
ing paclitaxel-containing regimens, and paclitaxel dose inten-
sity is related to the occurrence of severe neurotoxicities, espe-
cially when combined with cisplatin, therefore cisplatin is
commonly replaced with carboplatin. However, the paclita-
xel/carboplatin regimen causes more myelosuppression. In
this study, grade 3 or 4 neuropathy developed in 6% of pati-
ents receiving low-dose paclitaxel and cisplatin as a second-
line treatment, though 38% developed peripheral neuropa-
thy. This frequency of peripheral neuropathy for low-dose
paclitaxel/cisplatin regimen is similar to those of paclitaxel
and carboplatin regimens, which showed 50-85% peripher-
al neuropathy of all grades and 0-8% grade 3 or 4 peripher-
al neuropathy, respectively (14, 21, 30). Moreover, compared
with docetaxel-containing regimens, the low-dose paclitax-
el/cisplatin combination appears to have a favorable toxicity
profile, particularly with respect to myelosuppression.
We observed that this combination therapy produced 25%
response rate, which is similar to 22-28% in previously treat-
ed gastric cancer patients who received higher doses of pacli-
Second-line Paclitaxel/Cisplatin for Gastric Cancer S119taxel (175-200 mg/m2) and carboplatin as a second-line the-
rapy (21, 30). TTP was shorter than expected (median, 2.9
months), which may be due to the patients’ prior chemother-
apy regimens, all of which included platinum-based agents.
The median OS for all patients was 9.1 months from the start
of second-line chemotherapy, despite a short TTP, which is
probably explained in part by the administration of additional
salvage chemotherapy (i.e., third-line treatment) in 23 patients
(72%). Although the role of third-line chemotherapy is still
controversial in gastric cancer, our results suggest that third-
line chemotherapy may result in substantial prolongation of
survival and warrant further prospective evaluation.
In conclusion, low-dose paclitaxel and cisplatin chemother-
apy showed moderate activity with favorable toxicity profiles
as a second-line treatment for patients with advanced gastric
cancer who had failed 5-FU and platinum-based chemothera-
py. However, relatively short TTP of this regimen warrants
the development of more effective paclitaxel-based regimens
other than combination with cisplatin in these patients as
potential second-line therapies. 
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